Sanofi SA (SNY) on Friday announced that the pivotal LIBERTY-AFRS-AIMS phase 3 study of Dupixent, co-developed with Regeneron Pharmaceuticals Inc. (REGN), for the treatment of individuals aged 6 years and older with allergic fungal rhinosinusitis (AFRS), has met its primary endpoint.
AFRS is a chronic type 2 inflammatory disease of the sinuses characterized by allergic hypersensitivity to fungi.
The study showed that Dupixent significantly improved signs and symptoms, including reductions in sinus opacification, nasal congestion, and nasal polyps, compared with placebo.
Recently, the U.S. Food and Drug Administration (FDA) accepted the supplemental biologics license application (sBLA) for Dupixent for priority review, with a target action date of February 28, 2026.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.